JOINN (06127) rose over 7% against the broader market trend. At the time of writing, the stock was up 7.42% to HK$21.26, with a turnover of HK$122 million.

Recently, JOINN released its first-quarter report for 2026. Revenue reached RMB 316 million, a year-on-year increase of 10.02%. Net profit attributable to shareholders was RMB 238 million, surging approximately 479.67% year-on-year. Basic earnings per share were RMB 0.32.

According to analysis, the company's first-quarter performance met expectations, with newly signed orders more than doubling. Specifically, new orders in the first quarter amounted to RMB 910 million, a year-on-year increase of 111.6%. The backlog of orders at the end of the period stood at RMB 3.1 billion, up 40.9% year-on-year, laying a solid foundation for future performance growth.

The analysis further notes that considering ongoing domestic policies encouraging innovation, coupled with active performance in A+H innovative drug stocks and a recovery trend in IPOs, domestic demand is expected to see marginal improvement in the coming years. As a core participant in China's preclinical CRO business, the company is positioned to benefit significantly from this trend.